News
HLX22 received orphan drug designation, offering incentives like tax credits and market exclusivity to accelerate development for gastric cancer treatment. Phase 2 trial results showed HLX22 improved ...
As of 3:30:16 p.m. EDT. Market Open.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback